Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ADHD one of the best symbols ever If they make drugs for ADHD treatment. Lol
I'm not looking for much here, just a 100%~200% gain. That's all I aim for. Can't get greedy you know... ;)
I got some shares at .135 too. ;)
I didn't buy that much. Were you dumping? lol
that's one of the reasons why i got back in ljpc after it popped last week.
still got a solid event coming up.
i wonder what happened with xoma... dropped pretty badly but i didn't bother to read any filings or PRs. maybe it's a good time to tip toe in xoma?
ETRM dropped about 4% today after hitting resistance. Looks to me like taking profit near a known resistance is never a bad strategy. I'm going for small hits anyway rather than falling in love with the stock.
yeah this stock taking forever to move. but looks like it's gonna move any day now
RGDX bought more. Lots of catalysts for this stock!
$SGLB grabbed some here. Looks to have bottomed out nicely
$CIMT ran into some resistance that's all. I got some more on this dip.
Catalyst is too far out maybe.
$LJPC I guess this explains why there was an analyst report out, saw it go up to $10 and then the stock dropped back down
Feb 26 note conversion 1.17 million shares. http://ih.advfn.com/p.php?pid=nmona&article=61307731
$CMXI nice recovery today.
hydrogen fuel cells are promising, imo
A B C D E F G!
$ADMP Anybody still in this?
RGDX and QRXPY are both holding up well. QRXPY is OTCQX with May 2014 PDUFA
I'm down like $6k today... gotta get used to these wide swings with the increasing volatility. WEEEEEEE
over all bio market tanked today
it really is a Winter again... Freezing my nuts off today
DARA EXAS LJPC RGDX bought some more.
DARA / LJPC I am back in. as well. Planning on holding both for a while
$ADMP - other than PR rumors, what's the nearest solid catalyst date for this? Seems an NDA would take several months after filing assuming it's accepted. Takes almost a year don't they? Also inhaler trials have not started yet.
Baker brothers are still in? Hopefully they didn't dump yesterday
Lol
LJPC back in as well. Got some 7.70s earlier.
Got back in... Entered about 50% so far, getting some more later.
Should be good
other than PR rumors, what's the nearest solid catalyst for this? Seems to me that an NDA PR would take several months after filing assuming it's accepted.
Takes almost a year don't they?
Also inhaler trials have not started yet.
((( SIGN UP FOR MEGA ALERTS )))
http://www.matrixpennystocks.com
((( SIGN UP FOR MEGA ALERTS )))
http://www.matrixpennystocks.com
$DARA banked 40%
$OREX / $QRXPY holding in at $7.23 / $3.93 respectively
$ADMP in @ $6.72 holding and adding more...
Adamis Pharmaceuticals. Recently uplisted to NASDAQ. Market cap $62M
ADMP -> CRT capital group initiated with buy recently and $15 PT REPORT and some of the catalyst reported are here:
Some key points from report: "Having recently acquired the exclusive rights to 3M’s multi-dose dry powder inhaler (DPI),we believe there is the potential for Adamis to develop a competing product to GSK’s Advair Diskus by 2017."
* " In addition, the Company plans on filing an epinephrine pre-filled syringe (forthe treatment of anaphylaxis) product by Q1’14, which could be commercialized by year end."
• In Q1 2014, Adamis plans on filing its epinephrine pre-filled syringe to the FDA via the 505(b)(2) pathway. The Company expects to hear back on an approval decision by late 2014/early 2015. Adamis is partnered with Catalent, who is the contract manufacturer.
• By mid-2014, Adamis plans to conduct a small, 80-patient study with its Taper Dry owder Inhaler (DPI) for treatment of COPD/asthma. We believe the main purpose of
this trial will be to demonstrate the comparable efficacy profile of its recently acquired inhaler vs. GSK’s Advair (the “gold standard” product in the market). We believe this trial could be completed by Q4’14. Adamis will be supplied the product by 3M.
• By mid’14, we believe Adamis will look to meet with the FDA to discuss its development plans on APC-1000 (beclomethasone inhaler - comparable to TEVA’s QVAR). We believe Adamis has plans to run a Phase 3 study evaluating the efficacy of its product vs. Qvar. On this product, Adamis is partnered with Beximco.
• By late 2014, we believe Adamis could secure additional partners for its Taper Dry Powder Inhaler for international markets. We would not rule out Adamis also looking for potential partners for its APC-1000 beclomethasone product.
Full report can be found here: https://docs.google.com/file/d/0Bwgu6jYVrAKiZDVfRWpPZ2E4b0hOc2p0LUZ5MlA4OFFxM0xj/edit?pli=1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=97574609&txt2find=admp
$ADMP holding and adding more
Adamis Pharmaceuticals. Recently uplisted to NASDAQ. Market cap $62M
ADMP -> CRT capital group initiated with buy recently and $15 PT REPORT and some of the catalyst reported are here:
Some key points from report: "Having recently acquired the exclusive rights to 3M’s multi-dose dry powder inhaler (DPI),we believe there is the potential for Adamis to develop a competing product to GSK’s Advair Diskus by 2017."
* " In addition, the Company plans on filing an epinephrine pre-filled syringe (forthe treatment of anaphylaxis) product by Q1’14, which could be commercialized by year end."
• In Q1 2014, Adamis plans on filing its epinephrine pre-filled syringe to the FDA via the 505(b)(2) pathway. The Company expects to hear back on an approval decision by late 2014/early 2015. Adamis is partnered with Catalent, who is the contract manufacturer.
• By mid-2014, Adamis plans to conduct a small, 80-patient study with its Taper Dry owder Inhaler (DPI) for treatment of COPD/asthma. We believe the main purpose of
this trial will be to demonstrate the comparable efficacy profile of its recently acquired inhaler vs. GSK’s Advair (the “gold standard” product in the market). We believe this trial could be completed by Q4’14. Adamis will be supplied the product by 3M.
• By mid’14, we believe Adamis will look to meet with the FDA to discuss its development plans on APC-1000 (beclomethasone inhaler - comparable to TEVA’s QVAR). We believe Adamis has plans to run a Phase 3 study evaluating the efficacy of its product vs. Qvar. On this product, Adamis is partnered with Beximco.
• By late 2014, we believe Adamis could secure additional partners for its Taper Dry Powder Inhaler for international markets. We would not rule out Adamis also looking for potential partners for its APC-1000 beclomethasone product.
Full report can be found here: https://docs.google.com/file/d/0Bwgu6jYVrAKiZDVfRWpPZ2E4b0hOc2p0LUZ5MlA4OFFxM0xj/edit?pli=1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=97574609&txt2find=admp